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Ambulatory External Electrocardiographic Monitoring
Focus on Atrial Fibrillation
Suneet Mittal, MD,* Colin Movsowitz, MBCHB,† Jonathan S. Steinberg, MD*
New York, New York; and Wynnewood, Pennsylvania
There has been progressive development in ambulatory external electrocardiogram (AECG) monitoring technol-
ogy. AECG monitors initially consisted of 24- to 48-h Holter monitors and patient-activated event and loop re-
corders. More recently, several ambulatory cardiovascular telemetry monitors and a patch-type 7- to 14-day
Holter monitor have been introduced. These monitoring systems are reviewed along with their utility and limita-
tions, with particular emphasis on their role in the diagnosis and evaluation of patients with atrial fibrillation
(AF). AECG monitoring is necessary when asymptomatic AF is suspected (as in patients presenting with crypto-
genic stroke) or when an ECG diagnosis of unexplained arrhythmic symptoms is warranted. In addition, AECG
plays an important role in patients with known AF to guide ventricular rate control and anticoagulation therapy,
and assess the efficacy of antiarrhythmic drug therapy and/or ablation procedures. Finally, we outline areas of
uncertainty and provide recommendations for use of available AECG monitors in clinical practice. (J Am Coll
Cardiol 2011;58:1741–9) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.07.026The 12-lead electrocardiogram (ECG) has served as the
“gold standard” for arrhythmia diagnosis for over a hundred
years. However, for nearly as long, the limitations inherent
to an ECG have also been recognized. Arrhythmias can be
paroxysmal and asymptomatic; thus, a baseline resting ECG
may be insufficient for diagnosis. Atrial fibrillation (AF) is
the prototypical example of an arrhythmia in which a
12-lead ECG is insufficient to guide clinical management.
Since the development of the Holter monitor in the 1940s,
there has been progressive development in ambulatory
external electrocardiogram (AECG) monitoring technology
(Fig. 1). This reviews focuses on these new technologies
with an emphasis on their role in the diagnosis and
management of patients with AF.
Types of Available AECG Monitors
Holter, event, and loop monitors. The 1999 practice
guidelines released jointly by the American College of
Cardiology and the American Heart Association catego-
rized AECG monitors as either continuous short-term
recorders (24 to 48 h) or intermittent longer-term recorders
(patient-activated event and loop recorders) (1). During
Holter monitoring, a patient is typically connected to 3 to 5
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accepted July 20, 2011.ECG electrodes, which yield 2 ECG vectors and a third
derived electrogram. Some systems can also derive a 12-lead
ECG recording, which can be useful to evaluate the QRS
morphology. The ECG signals are acquired at up to 1,000
samples per second, which yield high-fidelity tracings. The
patient maintains a diary to document the time when
symptoms are experienced and their description. After the
1- to 2-day recording period is completed, the patient
returns the monitor; the data stored within the flashcard
memory are digitized and downloaded to a local workstation
or transmitted over the Internet to a central workstation.
Only then can it be determined whether the ECG tracings
were of adequate quality and whether any diagnostic infor-
mation was obtained. The computer-scanned Holter re-
cording is read by a trained technician who then forwards
the report to the physician for final review and official
interpretation. Assuming that the recording quality is ade-
quate, Holter monitors can determine the average heart rate
and heart rate range, quantify atrial and ventricular ectopy
counts, and determine whether AF is present. Information
about shortest and longest duration of AF, burden of AF,
the heart rate during AF, and pattern of initiation and
termination of AF can also be determined.
Patient-activated event and loop recorders can be used for
several weeks at a time. Event recorders are small, leadless
devices that are carried by the patient. When a patient
experiences a symptom, the device is applied to the chest
wall. Since electrodes are present on the back of the device,
a brief (typically up to 90 s) single-lead ECG recording can
be stored. The event recorder can store only a few tracings
since they have only about 10 min of storage capacity; thus,
1742 Mittal et al. JACC Vol. 58, No. 17, 2011
Ambulatory ECG Monitoring October 18, 2011:1741–9to minimize loss of data, once an
event is recorded, it needs to be
immediately transmitted tran-
stelephonically (using an acoustic
coupler modem) to a central
monitoring site for validation
and analysis. By design, event
recorders do not provide infor-
mation about asymptomatic episodes.
Loop recorders on the other hand require that ECG leads
be attached to the patient. As new ECG data are collected,
older ECG data are deleted. When a patient activates the
device, it stores a single-lead ECG before (typically about
45 to 60 s) and after (typically about 15 to 90 s) activation.
As with event recorders, the devices have limited memory.
Thus, to minimize loss of critical data, immediate transtele-
phonic data transmission following a symptomatic episode
is necessary.
By design, loop recorders also do not provide information
about asymptomatic episodes. To overcome this limitation,
auto-triggered loop recorders were developed. These devices
use a proprietary algorithm to trigger ECG storage of
arrhythmic episodes such as bradycardia (including pro-
longed pauses), tachycardia, and atrial fibrillation. The
available memory, typically 10 to 20 min in duration, is
partitioned for patient-triggered and auto-triggered events.
The device alerts (e.g., with a beeping noise) the patient
when an auto-triggered event has been detected. The
patient must transmit the data transtelephonically to a
central monitoring station for review. It has been shown
that these auto-triggered devices have higher diagnostic
yield than standard 24-h Holter monitors and 30-day loop
recorders (2). Auto-triggered loop recorders have evolved
capability of transmitting stored ECG data wirelessly to a
device that can then send data to a central monitoring
station over a landline or cellular telephone network. Al-
though these monitors can detect the onset of an arrhythmia
such as AF, their algorithms are not designed to detect the
offset of the arrhythmia. Thus, information about the
burden of AF cannot be consistently ascertained. As a result,
these types of monitors have fallen out of favor in our
practice.
Ambulatory telemetry and patch-type monitors. Ambu-
latory telemetry monitoring was developed to overcome
many of the limitations inherent to Holter, event, and
loop monitoring, namely the need for long-term moni-
toring and the ability to capture information about
symptomatic and asymptomatic arrhythmias. Currently,
several systems are available in the United States (Table 1,
Fig. 1B). Typically, patients are connected by 3 or 4 ECG
electrodes to a battery-powered sensor for up to 30 days.
The sensor can hold anywhere from 6 h to all 30 days of
ECG data. In a “sensor-only” system, when the patient is
in a location with available cellular coverage, the stored
ECG data are transmitted directly to a central monitor-
Abbreviations
and Acronyms
AECG  ambulatory
external electrocardiogram
AF  atrial fibrillation
ECG  electrocardiograming station. More commonly, systems incorporate asecond handheld device. In this case, data from the sensor
is sent to the handheld device when it is within 10 to 300
feet of the patient. Once the patient is in a location with
available cellular coverage, the stored ECG data are
transmitted from the handheld device to a central mon-
itoring station. Patients can also use the handheld device
to enter information about symptoms. The monitoring
center can determine whether the patient is actually
wearing the device and ascertain the quality of the contact
with the ECG electrodes; by communicating directly
with the patient, the compliance with the system and
quality of the acquired data may be improved.
Currently available systems handle incoming ECG data
differently. Some “push” ECG data to a central monitoring
station only when the handheld device confirms that a
bradycardic or tachycardic arrhythmia (including AF)
event has occurred, based on proprietary algorithms that
incorporate (depending on the vendor) information about
rate, rhythm, and/or P and QRS morphology. Other
systems push all ECG data forward. Since these devices
capture information about symptomatic and asymptom-
atic events, information about AF burden during the
recording period can also be ascertained. Not surpris-
ingly, compared with loop monitoring, these systems
significantly increase the likelihood of detecting AF (3).
In addition to getting a summary report at the end of the
recording period (either by fax or online), practices can
develop their own emergent, urgent, and routine physi-
cian notification criteria.
Several issues with AECG monitoring systems merit
comment. First, since the sensor captures beat-by-beat data,
complete ECG analysis (like a Holter recording) should be
available either intermittently or at the end of the recording
period. However, currently only a few vendors offer this
analysis, often only upon a specific request from a physician.
Thus, physicians typically just assume ECG data has been
appropriately recorded, scanned, and analyzed. Second,
although touted as “real-time” telemetry, only 2 of these
systems actually function in this manner (Table 1). One
system sends ECG data from the sensor to a handheld
device, which in turn forwards the accrued ECG informa-
tion every 2 min to a central monitoring station. A physician
can access the data over a secure web server. A second
system transfers ECG data directly from the sensor to a
central monitoring system. In this system, the physician has
the ability to access real-time streaming ECG data from
their patient on any computer with Internet access. Third,
although critical data are made available to physicians on a
24 h/7 days a week basis and routine data on a daily basis,
reimbursement to physicians does not take into account the
need for daily monitoring for up to a month. Thus, although
physicians must assume the responsibility for monitoring
daily incoming data, the reimbursement to physicians for
ambulatory cardiovascular telemetry is actually lower than
that for Holter monitoring (Table 2). The majority of the
reimbursement is collected by the independent diagnostic
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(A) Holter, event, and loop monitoring; (B) patch-type extended Holter and ambulatory telemetry monitoring. AECG  ambulatory external electrocardiographic;
ECG  electrocardiographic. Figure illustration by Craig Skaggs.
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On the other hand, there is no mechanism for physicians to
be reimbursed daily for their review of incoming ECG data.
Since appropriate use guidelines for this type of ECG
monitor have not yet been developed, some commercial
carriers do not provide coverage or reimbursement at all
on the grounds that mobile cardiovascular telemetry
monitoring is “investigational.” In addition, the absence
of guidelines has to led to uncertainty regarding the
potential liability for “missed” critical arrhythmic events.
Fortunately, although these monitoring systems detect
many arrhythmic events, only 1% can ultimately be
classified as emergent (4).
A recently developed alternative (Zio Patch, iRhythm
Technologies, San Francisco, California) utilizes a small,
lightweight, water-resistant patch that is placed in the left
pectoral region and can store up to 14 days of continuous
single-lead ECG data. A button on the patch can be pressed
by the patient to mark a symptomatic episode. At the end of
the recording period, the patient mails back the recorder in
a pre-paid envelope to a central station (much like a Netflix
DVD). A proprietary algorithm can process 14 days of
acquired data within 10 min. A full report is provided to the
ordering physician within a few days. Because the system
has not yet been made widely available, clinical experience is
currently lacking. It remains to be determined whether
patients can actually tolerate the patch for 7 to 14 days and
whether a set of near-field recording electrodes can yield a
high-quality, artifact-free ECG recording through the en-
tire recording period. Furthermore, the clinical implications
of not having access to ECG information within the
recording period need to be determined.
Indications for AECG Monitoring
Broadly speaking, the fundamental premise of AECG
monitoring is the potential to capture real-time rhythm
Commercially Available Ambulatory Telemetry Monitoring SystemshTable 1 Commercially Available Ambulatory Telemetry Monitor
Feature BioMedical Cardionet
Name TruVue MCOT
Single unit No No
Leads 3 3
Channels 2 2
Sampling rate 256 Hz 250 Hz
Sensor memory 30 days 30 days
Handheld/sensor interaction 100 ft 300 ft
2-way patient communication Yes Yes
24-h Holter analysis Yes No
Symptom correlation on screen Yes Yes
Auto/manual transmissions Yes Yes
QT/ST-segment analysis Yes No
Handheld device data storage capacity NA† NA†
Ability to visualize real-time ECG data Yes‡ No
*Upon request; †information stored on the sensor; ‡up to last 2 min; §streaming real-time.
ECG  electrocardiographic; NA  not applicable.recordings that can be used to: 1) provide an explanation foran unexplained prior or recurrent symptomatic event; or
2) capture arrhythmic events that aid in assessing prognosis
or treatment effect. Table 3 lists the currently accepted
indications, based on published evidence demonstrating
value in the assorted subcategories. A discussion of the
non-AF indications is beyond the scope of this paper and
has been the focus of other recent reviews (5); the use of
AECG in patients with AF will be reviewed in detail, as this
is an area of intense clinical and research interest.
Diagnosis of AF. When a patient presents with unex-
plained symptoms that suggest an arrhythmic mechanism,
AF is virtually always among the diagnostic considerations.
Symptoms of AF are very varied and include rapid or
abnormal heart action, weakness and fatigue, dyspnea,
physical limitations, polyuria, and others. Syncope is less
common as a direct result of AF, but may be due to
post-termination pauses, associated vagal phenomena, slow-
conducted ventricular rates, hemodynamic compromise in
the presence of severe structural heart disease, or proar-
rhythmia due to drug therapy. Hence, prolonged AECG
recording becomes very valuable to sort out these possibil-
ities, to clarify the need for additional treatment, to help
reassure the patient and to project long-term prognosis.
Diagnosis of AF as the cause of cryptogenic stroke.
Twenty-five percent of ischemic strokes remain unexplained
after an initial thorough evaluation including 12-lead ECG
and in-hospital telemetry monitoring and are designated
cryptogenic stroke. AF is the most common cardioembolic
source of ischemic stroke. Because the presence of AF will
lead to a specific and effective medical intervention in this
setting, that is, chronic oral anticoagulation to prevent
recurrent stroke, it is critical to identify the 10% of patients
whose index stroke was caused by AF (6). In about 5% of
patients, this effort is made simple when AF is present on
ECG or telemetry during the index hospitalization (7).
However, prolonged outpatient monitoring will extend the
ystemsh
LifeWatch Medicomp MedNet ScottCare
ACT III ACT I SAVI ECAT TeleSentry
No No No No Yes
4 3 3 3 3, 5, 12
3 1 2 2 3, 12
50 Hz 250 Hz 250 Hz 205 Hz 200 Hz
6 h 6 h 4 days 30 days 30 days
10 ft 10 ft 15 ft 30 ft NA
Yes Yes Yes Yes No
Yes* No Yes No Yes
Yes Yes Yes No No
Yes Yes Yes Yes Yes
Yes* Yes Yes No No
8 days 28 days 30 days NA† NA†
No No No No Yes§ing S
2
2diagnosis of AF to an additional 6% to 8% of patients, with
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October 18, 2011:1741–9 Ambulatory ECG Monitoring2011 CPT Codes for AECG Monitoring, Medicare Fee Schedule, and Approved IndicationsTable 2 2011 CPT Codes for AECG onitoring, Medicare Fee Schedule, and Approved Indications
Technology CPT Description Reimbursement Indications
Holter monitors (up to 48 h;
up to twice every
6 months)
93224 External electrocardiographic recording up to
48 h by continuous rhythm recording and
storage; includes recording, scanning
analysis with report, physician review and
interpretation (global)
$118.64 Detection of transient episodes of cardiac
dysrhythmias, permitting correlation of
these episodes with current cardiovascular
symptomology
93225 Recording (includes connection, recording, and
disconnection)
$35.57 Detection of abnormalities of cardiac rhythm
or electrocardiographic morphology
associated with symptoms of syncope,
near-syncope, palpitations, chest pain
suggestive of cardiac ischemia, shortness
of breath on exertion, and recurrent
congestive heart failure where arrhythmia
is the suspected cause
93226 Scanning analysis with report $52.31 Evaluation of arrhythmias in the patient with
documented coronary artery disease,
including the assessment of the immediate
post-myocardial infarction patient
93227 Physician review and interpretation $30.57 Detection of arrhythmias (such as atrial
fibrillation) in patients with acute stroke or TIAs
Assessment of patients with implanted
pacemakers or defibrillators, but only when
patients have symptoms suggestive of
arrhythmia not revealed by the standard
ECG or defibrillator event recordings, or by
analysis of the pacemaker or defibrillator
devices
Monitoring the effectiveness of antiarrhythmic
therapy
Event monitors (up to
30 days; no defined
frequency limit)
93268 External patient and, when performed,
autoactivated electrocardiographic
rhythm–derived event recording with
symptom-related memory loop with remote
download capability up to 30 days, 24-h
attended monitoring; transmission of data
and physician review and interpretation of
the data (global)
$313.03 No defined guidelines
93270 Recording (includes connection, recording, and
disconnection)
$19.27
93271 Transmission download and analysis $264.73
93272 Physician review and interpretation $29.04
Mobile cardiovascular
telemetry (up to
30 days; once every
6 months)
92229 Wearable mobile cardiovascular telemetry with
electrocardiographic recording, concurrent
computerized real-time data analysis and
24 h of accessible ECG data storage
(retrievable with query) with ECG-triggered
and patient-selected events transmitted to a
remote attended surveillance center for up
to 30 days; technical support for connection
and patient instructions for use, attended
surveillance, analysis and physician-
prescribed transmission of daily and
emergent data reports
$860.35* Detection, characterization, and
documentation of symptomatic transient
arrhythmias, when the frequency of the
symptoms is limited and use of a 24-h
ambulatory ECG is unlikely to capture and
document the arrhythmia
Regulation of antiarrhythmic drug dosage,
when needed to assess efficacy of
treatment
To ensure the absence of atrial fibrillation
prior to the discontinuation of
anticoagulation therapy
To monitor patients who have had surgical or
ablative procedures for arrhythmias
93228 Wearable mobile cardiovascular telemetry with
electrocardiographic recording, concurrent
computerized real-time data analysis and
24 h of accessible ECG data storage
(retrievable with query) with ECG-triggered
and patient-selected events transmitted to a
remote attended surveillance center for up
to 30 days; physician review and
interpretation with report
$28.95
*Coverage for mobile cardiovascular telemetry monitoring from commercial insurance carriers varies from state to state; several carriers consider the service “investigational” and, thus, provide no
reimbursement.
AECG  ambulatory external electrocardiographic; CPT  Current Procedural Terminology; ECG  electrocardiographic; TIA  transient ischemic attack.
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when AF is asymptomatic. Because paroxysmal AF is as
likely as continuous AF to increase the risk of stroke (10),
there is inherent logic in searching for the presence of
transient AF over longer periods of surveillance. The ap-
propriate duration of monitoring has not been determined
with certainty, but present-day monitors that autocapture
AF events accurately over a 21- to 30-day period seem
justified. Tayal et al. (11) initiated 21-day mobile cardiac
outpatient telemetry after hospitalization in 56 patients with
cryptogenic stroke and identified new AF in 23%, although
many patients had only AF of uncertain significance, lasting
30 s. The ongoing study CRYSTAL-AF (Study of Con-
tinuous Cardiac Monitoring to Assess Atrial Fibrillation
After Cryptogenic Stroke) (12) is investigating the value of
even longer-term monitoring using an implantable loop
recorder, emphasizing the importance of identifying which
patients with cryptogenic stroke should be candidates for
anticoagulation.
Monitoring AF. AF is a chronic condition, and once the
diagnosis has been established, periodic monitoring is nec-
essary for a variety of reasons. The management of parox-
ysmal versus persistent AF may differ. When presented with
a patient in AF in the office setting, it may be difficult to
Indications for AECG MonitoringTable 3 Indications for AECG Monitoring
AF indications
Diagnosis of AF
Unexplained arrhythmic symptoms
Cryptogenic stroke
Evaluation of known AF
Differentiate paroxysmal vs. persistent pattern
Compare heart rate in sinus rhythm vs. AF in tachy-brady patients
Evaluate adequacy of ventricular rate control during AF
Document pattern at initiation and termination of AF
Assess efficacy and complications of antiarrhythmic therapy or
ablation procedure
Ensure effective biventricular capture in patients with a
cardiac resynchronization therapy device
Non-AF indications
Unexplained symptoms
Palpitations, etc.
Pre-syncope or syncope
Recurrent unexplained falls
Risk stratification
T-wave alternans
Heart rate variability and heart rate turbulence
Nonsustained ventricular tachycardia in patients at risk of sudden death
(e.g., ischemic cardiomyopathy, hypertrophic cardiomyopathy,
arrhythmogenic right ventricular cardiomyopathy)
Miscellaneous
Quantify burden and morphology of repetitive monomorphic
ventricular ectopy
Assess device function (i.e., sensing and pacing)
ST-segment analysis
QT interval
AF  atrial fibrillation; tachy-brady  tachycardic/bradycardic; other abbreviations as in Table 2.confidently determine whether the AF pattern is likely to be tcontinuous or episodic, and thus recording an AECG over
the course of 1 or more weeks may be useful. The evolution
to persistent AF may be insidious but may suggest the need
for more aggressive intervention including cardioversion,
antiarrhythmic drug therapy, more intensive rate control
regimens, specific ablation techniques (13), or reassessment
of prognosis and long-term treatment goals.
The AECG can also be utilized to more accurately
ascertain whether excessive ventricular rates are present, for
what portions of the day, and to what heights. It is generally
believed that exposure to excessive ventricular rates may risk
tachycardia-induced cardiomyopathy (14), and the 5-s rest-
ing ECG is inadequate to assess this risk and indeed may be
misleading. We advocate AECG recording of at least 24 h
for rate assessment, prior to and during titration of medical
therapy, usually targeting a resting ventricular rate of 80
beats/min and peak activity rates of 110 to 120 beats/min.
The RACE II (RAte Control Efficacy in Permanent Atrial
Fibrillation) study recently raised doubts about the need to
aggressively pursue this objective (15), but particularly in
heart failure patients, this treatment goal may still be
critical. The AECG will also facilitate simultaneous mon-
itoring of the main risk of aggressive rate control, excessive
bradycardia during AF, at termination, or in sinus rhythm.
At present, it is unknown whether 24 h is sufficient
sampling of ventricular rate or whether longer recording
durations would expose much greater day-to-day variability
than suspected.
Assessment of treatment efficacy. ANTIARRHYTHMIC
DRUG THERAPY. Antiarrhythmic drugs are primarily used
o reduce AF prevalence in highly symptomatic individuals,
ut are assumed to be incapable of complete AF eradication
n most patients. Patients with stroke risk factors are
elieved to be at continued risk, and chronic anticoagulation
herapy is recommended (16). Thus, it is less important to
erform AECG monitoring to confirm AF suppression in
ntiarrhythmic drug–treated patients.
CATHETER ABLATION. Percutaneous catheter procedures
esigned to eliminate the likely triggers of AF (usually the
ulmonary veins) and sometimes directed to atrial substrate
re increasingly used to control AF and its symptoms when
edical therapy has been ineffective (13,17,18). AECG
ecording is often employed after the procedure has been
ompleted and can play several roles: follow AF patterns
uring the early “blanking period”; clarify the cause of
esidual symptoms if present; detect asymptomatic AF; and,
otentially, confirm the eradication of AF and thus the
ong-term prognosis and the need for continued medical
herapy including anticoagulation.
In the weeks and first few months following ablation of
F, it has been noted that many patients may continue to
xperience arrhythmias that ultimately or gradually dissipate
nd do not portend failure to definitively respond to the
rocedure. In a study designed to comprehensively define
he blanking period, Joshi et al. (19) performed continuous
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October 18, 2011:1741–9 Ambulatory ECG Monitoringoutpatient AECG with a device that utilized autodetection
algorithms to capture all AF events greater than 30 s in
duration over the first 3 months following ablation in 72
patients. Overall, 65% of patients had at least 1 AF event.
The presence of AF during any of the 2-week epochs
throughout this early follow-up period did not predict the
ultimate response to the procedure (AF suppression in 72%
of the cohort, as adjudicated at 6 months), but the absence
of AF in the first 2 weeks had a 90% sensitivity for
predicting absence of AF in the long-term. This observation
would suggest that in the select patients with heavy symp-
tomatic AF burden who undergo ablation, the absence of
AF during early AECG monitoring may allow early dis-
continuation of intense outpatient ECG monitoring. After
the blanking period has expired, the focus on post-ablation
care is the determination of whether the patient has
responded and to what degree. Symptom status will
certainly be of value, but studies suggest that as many as
one-half of the episodes of AF may be asymptomatic
after ablation (20 –22) and that ablation itself may in-
crease the proportion of asymptomatic events (23) versus
the pre-ablation pattern, perhaps by ablation of cardiac
neuronal connections, placebo effect, or concomitant
medical therapy. Thus, monitoring is an important tool
to assess arrhythmia status post-ablation for capture of
asymptomatic and symptomatic AF.
The optimal monitoring strategy has not been defined,
although expert consensus documents endorse the impor-
tance of periodic AECG (17). There is a continuum of
monitoring that can be entertained, ranging from the
minimal, 12-lead ECG recording at follow-up outpatient
visits, to the ideal that does not yet exist, a permanently
implanted and accurate wireless monitoring system (Fig. 2).
The latter is only approachable given present-day technol-
ogy with an implanted pacing device (pacemaker, defibril-
lator, resynchronization system) inserted for independent
indications, but these devices also have limitations related to
under- and oversensing, and must have an atrial lead.
Implantable loop recorders with continuous ECG recording
capability are potentially valuable (24) but are invasive, have
limited memory storage, can have frequent recordings gen-
Subopmal Ideal
Rhythm 12-lead ECG 24-hr 7 30 day ILR Permanent 
strip
  
Holter
-   
ECG monitor ECG Recorder 
With Wireless 
Transmission 
Figure 2 Spectrum of AECG Monitoring Modalities
As one moves from left to right, the duration of monitoring increases, which in
turn increases the diagnostic yield. ILR  implantable loop recorder; other
abbreviations as in Figure 1.serated by artifacts, and at present, have a lifespan of only
about 3 years.
CONFIRMING ADEQUACY OF BIVENTRICULAR PACING. Th-
re is no possibility of response to cardiac resynchronization
herapy (CRT) if effective ventricular capture does not occur
uring biventricular (BiV) pacing. The percentage of BiV
acing alone as recorded by the CRT device may be an
naccurate surrogate of complete and consistent BiV cap-
ure. Fusion and pseudo-fusion beats resulting from an
nteraction between intrinsically conducted and paced beats
ay be responsible for ineffective pacing, despite apparent
elivery of CRT as assessed by a high percentage of BiV
acing (25). Using 12-lead Holter ECG and template
atching, this hypothesis was tested in a recent study (26)
hat demonstrated that the absolute percentage of BiV
acing alone, as obtained from CRT device interrogation in
atients with permanent AF, was an unreliable surrogate of
ffective pacing. Although CRT devices documented90%
acing, in actuality, fusion and pseudo-fusion beats as
etermined on AECG constituted as much as 40% of the
verall paced beats in many patients, and only consistently
ffectively paced patients showed a favorable clinical re-
ponse and evidence of reverse remodeling following CRT.
reas of Uncertainty
lthough ambulatory cardiovascular telemetry monitoring
as emerged as a commonly used diagnostic tool in patients
ith suspected or known AF, some important concerns
ersist with respect to these systems. First, there are no
linical guidelines that guide practitioners on the use of
ECG monitoring in patients with AF. The last American
ollege of Cardiology/American Heart Association clinical
ompetence statement on electrocardiography and ambula-
ory electrocardiography was published in 1999 (1); at that
ime, neither auto-triggered loop recorders nor mobile
ardiovascular telemetry monitoring were commercially
vailable. In 2007, the Heart Rhythm Society, in conjunc-
ion with the European Heart Rhythm Association and
uropean Cardiac Arrhythmia Society, developed a consen-
us statement to provide recommendations in patients
ndergoing catheter or surgical ablation of AF (17). Al-
hough acknowledging that “the more intensively a patient
s monitored and the longer the period of monitoring, the
reater the likelihood of detecting both symptomatic and
symptomatic AF,” no specific guidelines were provided
egarding the optimal AECG monitoring system. Most
ecently, the European Society of Cardiology published
pdated guidelines for AF management (27). They suggest
hat “the intensity and duration of monitoring should be
etermined by the clinical need to establish the diagnosis,
nd should be driven mainly by the clinical impact of AF
etection. More intense AF recording is usually necessary in
linical trials than in clinical practice.” However, specific
ecommendations for which AECG monitoring system
hould be used are also not provided.
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of these systems for detecting AF. On October 28, 2003,
the Food and Drug Administration (FDA) released a
statement to guide industry interested in developing an
Arrhythmia Detector and Alarm system (28). For AECG
monitoring systems, testing needs to be performed accord-
ing to guidelines stipulated in a 1998 statement from the
American National Standard Institute and Association for
the Advancement of Medical Instrumentation (29). Any
system proposed to provide information on AF must be
tested against the Massachusetts Institute of Technology–
Beth Israel Hospital Arrhythmia Database (48 records of
30 min each) and the Noise Stress Test Database (12 ECG
records of 30 min plus 3 records of noise only). These
databases consist of digitized excerpts of 2-channel Holter-
type reference recordings, with each beat labeled by expert
cardiologist-annotators. Although industry needs to report
the sensitivity and specificity of their AF detection algo-
rithms to the FDA, comparative information across vendors
is not readily available. Furthermore, with only a single
exception (30), the details of the algorithm being used by
any given vendor for AF detection are not publically
available. Interestingly, although several vendors claim to
capture information on every ECG beat acquired during the
recording period, none have published the sensitivity and
specificity of their autodetect AF algorithm against the
“gold standard” of complete ECG data in the same patient.
Third, when ongoing monitoring for AF is required, both
ambulatory cardiovascular telemetry and extended Holter-
type recordings from a patch are available options. In
comparison to the patch, the 2 main advantages of ambu-
latory telemetry are access to data during the monitoring
Recommendations for Using AECG Monitoring in AF PatientsTable 4 Recommendations for Using AECG Monitoring in AF Pa
AECG Monitor Goal
24- to 48-h Holter Assess adequacy of ventricular rate co
persistent or permanent AF
Assess effective biventricular capture in
persistent or permanent AF in patien
cardiac resynchronization therapy de
Event recorder Elucidate mechanism of symptomatic
associated with hemodynamic comp
capable of employing this technolog
30-day ambulatory cardiovascular
telemetry monitors
Assess for asymptomatic AF in patient
cryptogenic stroke
Compare average heart rate in sinus rh
pattern of AF initiation and terminat
AF is paroxysmal or persistent
Routinely in the first month post pulmo
At 6 and 12 months post-ablation
Patient-activated loopmonitors (with and without automatic detection algorithms) do not offer any d
telemetry instead in these patients.
AAD  antiarrhythmic drug; AF  atrial fibrillation; ILR  implantable loop recorder; other abbreviatioperiod and the ability to monitor for up to a month.
Assuming that the patch technology could evolve to where
it, too, could offer a month of monitoring, there are no
compelling data to support the need for real-time access to
ECG data as opposed to receiving a singular report at the
conclusion of the recording period.
Finally, an emphasis of prolonged ECG monitoring
strategies has been the detection of arrhythmias. Even if we
assume that these monitors can detect arrhythmias with
perfect accuracy, it has yet to be demonstrated in clinical
trials that patient outcome is affected. In AF patients, an
important goal of monitoring is to use the data to guide
decisions regarding anticoagulation. However, before em-
barking down this road, we need to know what duration or
burden of AF is clinically important enough to warrant
initiation of anticoagulation and then develop an AECG
monitoring device that is capable of reliably accurately
detecting AF episodes of this duration or burden.
Conclusions
AECG monitoring often establishes a diagnosis of AF in a
given patient. Once established, AF is a chronic disease, and
AECG monitoring can be important to its long-term
management. Table 4 summarizes our current recommen-
ations for AECG monitoring in clinical practice. Techno-
ogic developments are necessary to produce an ECG
onitor that can be applied to any AF patient (preferable in
he office setting), can capture ECG information accurately
nd continuously, and can relay critical data to the physician
romptly without the need for patient participation. Finally,
uture studies need to address the impact of data acquired
s
Comment
patients with Role of longer term monitoring unknown
nts with
a
Requires 12-lead Holter monitor
mic episodes not
(in patients
If initial 30-day evaluation is nondiagnostic, may need
to consider ILR for longer-term ECG monitoring
If initial 30-day evaluation is nondiagnostic, may need
to consider ILR for longer-term ECG monitoring
vs. AF; assess
termine whether
Role of 7- to 14-day Holter patch remains unexplored
ein isolation Patients with no AF in the first 2 weeks have excellent
long-term outcome; AADs are weaned, and the
second 2-week period of monitoring is used to
assess the response
Helps define relationship between symptoms and
AF recurrences and assess burden of asymptomatic
AF; role of 7- to 14-day Holter patch remains
undefined
advantages for the detection or monitoring of AF. Thus, we routinely use ambulatory cardiovasculartient
ntrol in
patie
ts with
vice
arrhyth
romise
y)
s with
ythm
ion; de
nary v
istinctns as in Table 2.
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